Spectrum’s Zevalin Still Living In Rituxan’s Shadow, FDA Advertising Letter Shows
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA citations of Rituxan comparisons in a promotion for Zevalin throw added salt on old wounds for drug that has taken backseat to Rituxan’s blockbuster story.
You may also be interested in...
Promotions For Black-Box Drugs Aren’t Specific Enforcement Targets, FDA Says
FDA advertising enforcement does not preference black-box drugs despite risk-based approach prioritizing products with significant risks; nor are drugs with small patient populations exempt from risk-based approach.
Cancer Drug Zevalin May Finally Thrive Under Spectrum
The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.
Orphan Drug Spending: Could Sequence Of Indications Offer Pricing Policy Solution?
Focusing on orphan-first drugs may be best route to address pricing concerns, Health Affairs study suggests after finding that just one-fifth of spending on 15 top-selling partial orphan drugs was for the drugs’ rare disease indications.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: